Immuneering (IMRX) Directors and Executive Officers - CSIMarket
CSIMarket
 
Immuneering Corporation  (NASDAQ: IMRX)

Immuneering Corporation

Officers & Directors


Laurie B. Keating
Director

Peter Feinberg
Director

Mallory Morales
Chief Accounting Officer and Treasurer (Principal Financial and Accounting Officer)

Diana F. Hausman, MD
Director

Benjamin J. Zeskind
President, Chief Executive Officer and Director (Principal Executive Officer)

Ann E. Berman
Director

Robert J. Carpenter
Director

RSM US LLP
We have served as the Company.,

Immuneering Corporation currently has 53 employees.

  News about Immuneering Corporation Key Personnel

Amid Financial Hurdles, Immuneering Pursues Hope in the Fight Against Pancreatic Cancer,

Immuneering s Bold Move in Pancreatic Cancer Treatment Amid Financial ChallengesIn a high-stakes environment where the pharmaceutical industry is often fraught with both promise and peril, Immuneering Corporation s recent announcements have sparked a wave of enthusiasm and concern. The Cambridge-based biotech firm is on the precipice of critical data presentations and has secured a significant regulatory designation, yet it grapples with noteworthy financial struggles.Immuneering has revealed plans to present data from three arms of its ongoing Phase 2a trial of its drug candidate, IMM-1-104, slated for early January 2025. This trial, aimed at assessing the efficacy of IMM-1-104 in treating pancreatic canc...






IMRX Management Effectiveness IMRX Revenue per Employee IMRX Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.